No Data
No Data
Leerink Partners Initiates Molecular(MOLN.US) With Buy Rating, Announces Target Price $10
Molecular Partners' Novel CD3 Switch-DARPin Platform To Be Highlighted At SITC 2024 With Proof-Of-Concept Data
Molecular Partners Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a 212Pb-labeled Radio-DARPin Therapeutic Targeting DLL3 for Small Cell Lung Cancer Co-developed With Orano Med, at EANM 2024
Molecular Partners H1 Net Loss Narrows, Revenue Rises
Express News | Molecular Partners Adjusted H1 EPS $(0.88), Sales $4.75M
No Data
No Data